Gabapentin Withdrawal Syndrome : Clinical Neuropharmacology

Journal Logo

Advanced Search
Brief Reports

Gabapentin Withdrawal Syndrome

Norton, John W.

Author Information

Associate Professor of Neurology and Psychiatry, Director of Medical Psychiatry, University of Mississippi School of Medicine, Jackson, Mississippi, USA

Address correspondence to John W. Norton, Associate Professor of Neurology and Psychiatry, Director of Medical Psychiatry, University of Mississippi School of Medicine, 2500 North State St., Jackson, MS 39212.

Clinical Neuropharmacology 24(4):p 245-246, July 2001.

Abstract

Gabapentin (GBP) has gained wide acceptance in the treatment of pain, migraine, bipolar illness, and epilepsy. It has a relatively benign side effect profile, lacks significant drug interactions, is not liver metabolized, and is renally excreted. Herein three cases are presented that demonstrate withdrawal symptoms after abrupt discontinuation of GBP. Clinicians are encouraged to taper GBP dosage, especially when patients have taken high doses, and to warn patients of possible adverse effects of abruptly discontinuing GBP themselves.

© 2001 Lippincott Williams & Wilkins, Inc.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid